11 December 2023 Pfizer: XELJANZ® (tofacitinib citrate) PBS-listed for patients aged 2 years and older with active polyarticular course juvenile idiopathic arthritis (pcJIA) 0 minute read Pharma/Biotech By Cate Swannell Previous Post Next Post